The Green Paper \u2018Advancing our health: prevention in the 2020s\u2019 was published on 22 July 2019.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-07-24", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-07-24T06:37:56.79Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-07-19", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Preventive Medicine"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will publish the prevention Green Paper before the summer recess.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"} } , "tablingMemberConstituency" : {"_value" : "Scunthorpe"} , "tablingMemberPrinted" : [{"_value" : "Nic Dakin"} ], "uin" : "279415"} , {"_about" : "http://data.parliament.uk/resources/1140170", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1140170/answer", "answerText" : {"_value" : "
NHS England has acknowledged the recently published report and will be considering the content.<\/p>
Improving the prevention and treatment of heart attacks and stroke are key aims in the NHS Long Term Plan, with an important milestone being for the National Health Service to help prevent up to 150,000 heart attacks, strokes and dementia cases over the next 10 years. The NHS Long Term Plan highlights that outcomes from heart attack and stroke can be improved, and that there should be a focus on inequalities.<\/p>
<\/strong><\/p> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-23T16:54:04.3Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Heart Diseases and Strokes: Females"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will respond to the recommendations in the report entitled Call for Action: Inquiry into heart attack and stroke, published by the all-party Parliamentary group on women\u2019s health in July 2019; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4426", "label" : {"_value" : "Biography information for Paula Sherriff"}
}
, "tablingMemberConstituency" : {"_value" : "Dewsbury"}
, "tablingMemberPrinted" : [{"_value" : "Paula Sherriff"}
], "uin" : "279083"}
, {"_about" : "http://data.parliament.uk/resources/1140171", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1140171/answer", "answerText" : {"_value" : " Improving the prevention and treatment of heart attacks and stroke are key aims in the NHS Long Term Plan, with an important milestone being for the National Health Service to help prevent up to 150,000 heart attacks, strokes and dementia cases over the next 10 years. The NHS Long Term Plan highlights that outcomes from heart attack and stroke can be improved, and that there should be a focus on inequalities.<\/p> In addition, addressing variations in outcomes from cardiovascular disease (CVD), such as heart attacks and stroke, is one of Public Health England\u2019s (PHE) top priorities, and in February 2019, PHE announced new 10-year CVD ambitions for England, which are intended to complement the NHS Long Term Plan and are the first ever national ambitions to improve the detection and treatment of the major causes of CVD.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-23T16:48:22.11Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Heart Diseases and Strokes: Females"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve (a) outcomes, (b) early identification and (c) treatment of heart attack and stroke for women.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4426", "label" : {"_value" : "Biography information for Paula Sherriff"}
}
, "tablingMemberConstituency" : {"_value" : "Dewsbury"}
, "tablingMemberPrinted" : [{"_value" : "Paula Sherriff"}
], "uin" : "279084"}
, {"_about" : "http://data.parliament.uk/resources/1140209", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1140209/answer", "answerText" : {"_value" : " Discussions with Vertex, including meetings, are ongoing.<\/p> NHS England and NHS Improvement are leading the negotiations with Vertex and have made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients.<\/p> The Government fully supports NICE, NHS England and NHS Improvement in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department\u2019s approach remains to strongly urge Vertex to accept NHS England\u2019s and NHS Improvement\u2019s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "278929"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-23T16:49:59.47Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cystic Fibrosis: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent discussions there have been between Vertex Pharmaceuticals and NHS England with on cystic fibrosis medicines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1491", "label" : {"_value" : "Biography information for Kerry McCarthy"}
}
, "tablingMemberConstituency" : {"_value" : "Bristol East"}
, "tablingMemberPrinted" : [{"_value" : "Kerry McCarthy"}
], "uin" : "278928"}
, {"_about" : "http://data.parliament.uk/resources/1140210", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1140210/answer", "answerText" : {"_value" : " Discussions with Vertex, including meetings, are ongoing.<\/p> NHS England and NHS Improvement are leading the negotiations with Vertex and have made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients.<\/p> The Government fully supports NICE, NHS England and NHS Improvement in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department\u2019s approach remains to strongly urge Vertex to accept NHS England\u2019s and NHS Improvement\u2019s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "278928"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-23T16:49:59.517Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cystic Fibrosis: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will set a deadline for NHS England and Vertex Pharmaceuticals to come to an agreement to enable access to cystic fibrosis medicines produced by that company.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1491", "label" : {"_value" : "Biography information for Kerry McCarthy"}
}
, "tablingMemberConstituency" : {"_value" : "Bristol East"}
, "tablingMemberPrinted" : [{"_value" : "Kerry McCarthy"}
], "uin" : "278929"}
, {"_about" : "http://data.parliament.uk/resources/1140227", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1140227/answer", "answerText" : {"_value" : " Public Health England (PHE) advises that the guidelines of the International Commission on Non-Ionizing Radiation Protection (ICNIRP) should be adopted and there is no convincing evidence that radio wave exposures below the ICNIRP guideline levels cause adverse health effects. The ICNIRP guidelines cover exposures arising from new 5G base stations, as well as from older technologies.<\/p> Many exposure measurements have been made at publicly accessible locations near to mobile phone base stations, and these have consistently been well within guidelines. It is possible that there may be a small increase in overall exposure to radio waves when 5G is added to an existing network or in a new area; however, the overall exposure is expected to remain low relative to guidelines and as such there should be no consequences for public health.<\/p> <\/p> PHE has published information about exposure to the radio waves from mobile phone base stations, including those for 5G networks, at the following link:<\/p> <\/p>